Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
January 26 2023 - 7:26PM
Dow Jones News
By Sabela Ojea
Biogen Inc. said Thursday that the European Medicines Agency
committee has accepted a marketing authorization application for
its Alzheimer's drug.
Earlier this month, the Food and Drug Administration gave early
approval to the treatment, Lecanemab.
The drug should be delivered to patients diagnosed with a mild
cognitive impairment or a mild dementia stage of disease, Biogen
said.
The biotechnology company developed the treatment with
Tokyo-based Eisai Co., Ltd.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 26, 2023 19:11 ET (00:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024
